{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:06:37Z","timestamp":1792130797966,"version":"4.4.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1120,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate tolerability, clinical outcomes, and changes in NT-proBNP levels and glomerular filtration rate (GFR) in ATTR-CM patients treated with dapagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with stable, tafamidis-treated ATTR-CM were retrospectively evaluated at the initiation of dapagliflozin and 3 months thereafter. Tafamidis-treated ATTR-CM patients without SGLT2i served as a reference cohort. Overall, SLGT2i therapy was initiated in 34 patients. Seventeen patients with stable disease on tafamidis, who were subsequently started on dapagliflozin, were included in the analysis. Patients selected for SGLT2i presented with signs of advanced disease, evidenced by higher Gillmore disease stage (stage \u22652: 53% vs. 27.5%; P = 0.041), baseline median NT-proBNP [median (IQR) 2668 pg\/mL (1314\u20133451) vs. 1424 (810\u20132059); P = 0.038] and loop diuretic demand (76.5% vs. 45% of patients; P = 0.044), and lower LVEF (46.6 \u00b1 12.9 vs. 53.7 \u00b1 8.7%; P = 0.019) and GFR (51.8 \u00b1 16.5 vs. 68.5 \u00b1 18.6 mL\/min; P = 0.037) compared with the reference cohort. At 3-month follow-up, a numerical decrease in NT-proBNP levels was observed in 13\/17 (76.5%) patients in the dapagliflozin (\u2212190 pg\/mL, IQR: \u22121,028\u201371, P = 0.557) and 27\/40 (67.5%) of patients in the control cohort (\u2212115 pg\/mL, IQR: \u2212357\u2013105, P = 0.551). Other disease parameters remained stable and no adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In tafamidis-treated ATTR-CM patients, initiation of dapagliflozin was well tolerated. The efficacy of SGLT2i therapy in patients with ATTR-CM needs to be studied in randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14188","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T03:55:52Z","timestamp":1666151752000},"page":"397-404","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-9799","authenticated-orcid":false,"given":"Stephan","family":"Dobner","sequence":"first","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Bernhard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babken","family":"Asatryan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stortecky","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pilgrim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hunziker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"2026012114121038300_ehf214188-bib-0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"2","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012114121038300_ehf214188-bib-0002","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"20","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114121038300_ehf214188-bib-0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114121038300_ehf214188-bib-0004","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012114121038300_ehf214188-bib-0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012114121038300_ehf214188-bib-0006","article-title":"Lack of association between Neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"21","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012114121038300_ehf214188-bib-0007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamacardio.2021.0379","article-title":"Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: A prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial","volume":"1","author":"Butt","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012114121038300_ehf214188-bib-0008","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"7","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114121038300_ehf214188-bib-0009","volume-title":"KDIGO clinical practice guideline for acute kidney injury","year":"2012"},{"key":"2026012114121038300_ehf214188-bib-0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"14","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114121038300_ehf214188-bib-0011","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"21","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114121038300_ehf214188-bib-0012","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial","volume":"14","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2026012114121038300_ehf214188-bib-0013","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","article-title":"Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease","volume":"14","author":"Mason","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114121038300_ehf214188-bib-0014","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jacc.2021.07.045","article-title":"NT-proBNP response to heart failure therapies: An imperfect surrogate","volume":"28","author":"Cunningham","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114121038300_ehf214188-bib-0015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic importance of NT-proBNP and effect of Empagliflozin in the EMPEROR-reduced trial","volume":"28","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/397\/65108001\/eschf_10_1_397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/397\/65108001\/eschf_10_1_397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:13:30Z","timestamp":1769022810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/1\/397\/8304952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,19]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14188","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"2022-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}